C-Raf Kinase Inhibitor Pipeline Insight Report 2020: HyNap-Sora, Sorafenib/MG 010, APL-102, & BAL 3833 – ResearchAndMarkets.com | Financial Buzz

C-Raf Kinase Inhibitor Pipeline Insight Report 2020: HyNap-Sora, Sorafenib/MG 010, APL-102, & BAL 3833 – ResearchAndMarkets.com

The “C-Raf Kinase Inhibitor – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “C-Raf Kinase Inhibitor- Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in C-Raf Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

C-Raf Kinase Inhibitor Emerging Drugs

Sorafenib/MG 010 – Metagone Biotech

MG010 is a newly synthesized compound developed by Metagone. It is a C-Raf inhibitor, which demonstrates inhibition effect on mitochondrial C-Raf and the phosphorylated Death-Associated Protein Kinase (DAPK) complex in cancer cell together with another C-Raf inhibitor-Sorafenib. This MG-D-1609 causes mitochondria dysfunction, therefore, cut off energy supply and leading to cancer cell death. The MG-D-1609 can accurately identify and kill specific cancer cells, lower down the possibility of side effects and drug resistance.

The in vitro and in vivo results have showed the great efficacy of 1609 in lung, colorectal, kidney and liver cancer cell lines. Since the urgent need have this disease but lack of better options for patients suffered from above cancers. MG-D-1609 may be a breakthrough drug and expected to bring hope for patients with cancer patients. The MG-D-1609 is estimated to execute phase II clinical trial to prove the efficacy on lung, colorectal, liver and kidney cancer patients in Australia.

C-Raf Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different C-Raf Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in C-Raf Kinase Inhibitor

There are approx. 10+ key companies which are developing the therapies for C-Raf Kinase Inhibitor. The companies which have their C-Raf Kinase Inhibitor drug candidates in the most advanced stage, i.e. phase II include, Metagone Biotech etc.

Phases

This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

C-Raf Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

C-Raf Kinase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses C-Raf Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-Raf Kinase Inhibitor drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence C-Raf Kinase Inhibitor R&D.
  • In April 2019, Apollomics announced positive data for the Company’s multi-kinase inhibitor, APL-102, as both a single agent and in combination with an anti-PD-1 antibody in multiple preclinical studies.

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing C-Raf Kinase Inhibitor drugs?
  • How many C-Raf Kinase Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage acting as C-Raf Kinase Inhibitor?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the C-Raf Kinase Inhibitor therapeutics?
  • What are the clinical studies going on for C-Raf Kinase Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Amitech Therapeutic Solutions, Inc.
  • Basilea Pharmaceutica Ltd
  • CBT Pharmaceuticals Inc Chugai Pharmaceutical Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Redx Pharma Plc
  • Xspray
  • Metagone Biotech

Key Products

  • HyNap-Sora
  • Sorafenib/MG 010
  • APL-102
  • BAL 3833

Key Topics Covered:

Introduction

Executive Summary

C-Raf Kinase Inhibitor: Overview

  • Structure
  • Mechanism
  • Role in Cancer therapies
  • Significance
  • Application

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

C-Raf Kinase Inhibitor – Analytical Perspective

In-depth Commercial Assessment

  • C-Raf Kinase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends

C-Raf Kinase Inhibitor Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase I/II)

  • Comparative Analysis

Sorafenib/MG 010 – Metagone Biotech

  • Product Description
  • Research and Development
  • Product Development Activities

IND Stage Products

  • Comparative Analysis

APL-102: Apollomics

  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

HyNap-Sora: Xspray Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

Comparative Analysis

  • C-Raf Kinase Inhibitor Key Companies
  • C-Raf Kinase Inhibitor Key Products
  • C-Raf Kinase Inhibitor- Unmet Needs

C-Raf Kinase Inhibitor- Market Drivers and Barriers

  • C-Raf Kinase Inhibitor- Future Perspectives and Conclusion
  • C-Raf Kinase Inhibitor Analyst Views
  • C-Raf Kinase Inhibitor Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7q97w1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900